Genmab — November 2017
-
JohnW ; this was t
he reuters headline after the earnings call in august ; Genmab CEO confident to close some tech deals this year - http://www.reuters.com/article/brief-genmab-ceo-confident-to-close-some/brief-genmab-ceo-confident-to-close-some-tech-deals-this-year-idUSC7N1AJ01U?feedType=RSS&feedName=companyNews&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FcompanyNews+(News+%2F+US+%2F+Company+News) -
Vedr aftaler, husker jeg forkert eller var der ikke for nyligt tydelige indikationer fra Jan på at strategien med 50/50 tech deals havde vist sig for optimistisk? Hvis han er kommet til den erkendelse og dermed sænker kravene, bør der være større chancer for deals i nærmere fremtid
-
Angående isatuximab så forsøger de at finde mindre huller i Darzalex palette - lidt træls at Sanofi kommer først i fase III med CD38+Rev+Vel+Dex - synes det er lidt unødvendig at give den plads. Vi har dog Dara+Tha+Vel+Dex, men tænker det trækker ud, da det er et stort studie og ikke en kommerciel sponsor
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
